Af­ter build­ing ex­pec­ta­tions, the UK’s life sci­ences plan falls short of the hype

Mer­ck’s re­cent an­nounce­ment of a new re­search cen­ter in Lon­don like­ly whet­ted the UK life sci­ences sec­tor’s ap­petite for even big­ger news from the gov­ern­ment’s new in­dus­try plan, out to­day. But de­spite a con­sid­er­able amount of loy­al cheer­ing about post-Brex­it prepa­ra­tions, it doesn’t amount to near­ly enough to tip the eco­nom­ic scales in bio­phar­ma’s fa­vor.

And to be fair, what kind of of­fi­cial eco­nom­ic de­vel­op­ment plan, salt­ed with cor­po­rate projects, can do that, any­way?

Endpoints Premium

This article is for premium subscribers only

Upgrade to a premium subscription plan for unlimited access, and join our community of key biopharma players.